Next Article in Journal / Special Issue
Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance
Previous Article in Journal
Human Centred Design Considerations for Connected Health Devices for the Older Adult
Article Menu

Export Article

Open AccessArticle
J. Pers. Med. 2014, 4(2), 282-296; doi:10.3390/jpm4020282

Differential Transcriptome Profile of Peripheral White Cells to Identify Biomarkers Involved in Oxaliplatin Induced Neuropathy

1
Service of Oncology, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, 38010 Tenerife, Spain
2
Service of Medical Oncology, Hospiten Rambla, Hospiten Hospitals Group, Santa Cruz de Tenerife, 38001 Tenerife, Spain
3
Developmental Biology Laboratory, Department of Biochemistry and Molecular Biology, University of La Laguna, Av. Astrofísico Sánchez s/n, 38206 La Laguna, Spain
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Received: 25 March 2014 / Revised: 21 May 2014 / Accepted: 28 May 2014 / Published: 5 June 2014
(This article belongs to the Special Issue Personalized Cancer Therapy)
View Full-Text   |   Download PDF [693 KB, uploaded 5 June 2014]   |  

Abstract

Anticancer chemotherapy (CT) produces non-desirable effects on normal healthy cells and tissues. Oxaliplatin is widely used in the treatment of colorectal cancer and responsible for the development of sensory neuropathy in varying degrees, from complete tolerance to chronic neuropathic symptoms. We studied the differential gene expression of peripheral leukocytes in patients receiving oxaliplatin-based chemotherapy to find genes and pathways involved in oxaliplatin-induced peripheral neuropathy. Circulating white cells were obtained prior and after three cycles of FOLFOX or CAPOX chemotherapy from two groups of patients: with or without neuropathy. RNA was purified, and transcriptomes were analyzed. Differential transcriptomics revealed a total of 502 genes, which were significantly up- or down-regulated as a result of chemotherapy treatment. Nine of those genes were expressed in only one of two situations: CSHL1, GH1, KCMF1, IL36G and EFCAB8 turned off after CT, and CSRP2, IQGAP1, GNRH2, SMIM1 and C5orf17 turned on after CT. These genes are likely to be associated with the onset of oxaliplatin-induced peripheral neuropathy. The quantification of their expression in peripheral white cells may help to predict non-desirable side effects and, consequently, allow a better, more personalized chemotherapy. View Full-Text
Keywords: transcriptome profile; chemotherapy; oxaliplatin; neuropathy; FOLFOX; CAPOX; colon-adenocarcinoma transcriptome profile; chemotherapy; oxaliplatin; neuropathy; FOLFOX; CAPOX; colon-adenocarcinoma
Figures

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Supplementary material

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Morales, M.; Ávila, J.; González-Fernández, R.; Boronat, L.; Soriano, M.L.; Martín-Vasallo, P. Differential Transcriptome Profile of Peripheral White Cells to Identify Biomarkers Involved in Oxaliplatin Induced Neuropathy. J. Pers. Med. 2014, 4, 282-296.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Pers. Med. EISSN 2075-4426 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top